Literature DB >> 22212017

Scintigraphic evaluation of intra-arterial and intravenous regional limb perfusion of allogeneic bone marrow-derived mesenchymal stem cells in the normal equine distal limb using (99m) Tc-HMPAO.

A Sole1, M Spriet, L D Galuppo, K A Padgett, D L Borjesson, E R Wisner, R J Brosnan, M A Vidal.   

Abstract

REASONS FOR PERFORMING STUDY: Mesenchymal stem cells (MSCs) are commonly injected intralesionally for treatment of soft tissue injuries in the horse. Alternative routes of administration would be beneficial for treatment of lesions that cannot be accessed directly or to limit needle-induced iatrogenic damage to the surrounding tissue.
OBJECTIVES: The purpose of our study was to evaluate MSC distribution after intra-arterial (IA) and intravenous (IV) regional limb perfusions (RLP) using scintigraphy. We hypothesised that MSCs would persist in the distal limb after tourniquet removal and that both techniques would lead to diffuse MSC distribution.
METHODS: Six horses were used in the study. MSCs were labelled with hexamethyl propylene amine oxime (HMPAO) and technetium-99m. RLP was performed through the median artery of one forelimb and the cephalic vein of the opposite limb under general anaesthesia. The tourniquet was left in place for 45 min. Scintigraphic images were obtained at 0, 45, 75 min, 6 h and 24 h post injection.
RESULTS: Distribution of labelled MSCs through the entire distal limb was achieved with all 6 IA RLP, but 3 out of 6 IV RLP showed poor or absent uptake distal to the metacarpus. Mesenchymal stem cell persistence was 39% (30-60%) and 28% (14-50%) (median [minimum-maximum]) at 6 h for IA and IV RLP, respectively. Severe arterial thrombosis occurred in one horse after IA RLP.
CONCLUSIONS: Both IA and IV RLP of the distal limb result in MSC persistence in perfused tissues. The IA perfusion resulted in more reliable cell distribution to the pastern and foot area. POTENTIAL RELEVANCE: Regional limb perfusion of MSCs might be used in cases where intralesional injection is not possible or in order to avoid iatrogenic needle damage. Further work is needed to assess the safety of IA RLP before its clinical use.
© 2011 EVJ Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22212017     DOI: 10.1111/j.2042-3306.2011.00530.x

Source DB:  PubMed          Journal:  Equine Vet J        ISSN: 0425-1644            Impact factor:   2.888


  19 in total

1.  Effect of needle diameter on the viability of equine bone marrow derived mesenchymal stem cells.

Authors:  Hayley M Lang; Lauren V Schnabel; Jennifer M Cassano; Lisa A Fortier
Journal:  Vet Surg       Date:  2017-03-22       Impact factor: 1.495

2.  In Vivo Imaging and Tracking of Technetium-99m Labeled Bone Marrow Mesenchymal Stem Cells in Equine Tendinopathy.

Authors:  Jayesh Dudhia; Patricia Becerra; Miguel A Valdés; Francisco Neves; Neil G Hartman; Roger K W Smith
Journal:  J Vis Exp       Date:  2015-12-09       Impact factor: 1.355

3.  Allogeneic Mesenchymal Stem Cell Treatment Induces Specific Alloantibodies in Horses.

Authors:  Sean D Owens; Amir Kol; Naomi J Walker; Dori L Borjesson
Journal:  Stem Cells Int       Date:  2016-08-28       Impact factor: 5.443

4.  Equine Mesenchymal Stem/Stromal Cells Freeze-Dried Secretome (Lyosecretome) for the Treatment of Musculoskeletal Diseases: Production Process Validation and Batch Release Test for Clinical Use.

Authors:  Michela Mocchi; Stefano Grolli; Silvia Dotti; Dario Di Silvestre; Riccardo Villa; Priscilla Berni; Virna Conti; Giulia Passignani; Francesca Brambilla; Maurizio Del Bue; Laura Catenacci; Milena Sorrenti; Lorena Segale; Elia Bari; Pierluigi Mauri; Maria Luisa Torre; Sara Perteghella
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-10

5.  Equine mesenchymal stem cells from bone marrow, adipose tissue and umbilical cord: immunophenotypic characterization and differentiation potential.

Authors:  Danielle Jaqueta Barberini; Natália Pereira Paiva Freitas; Mariana Sartori Magnoni; Leandro Maia; Amanda Jerônimo Listoni; Marta Cristina Heckler; Mateus Jose Sudano; Marjorie Assis Golim; Fernanda da Cruz Landim-Alvarenga; Rogério Martins Amorim
Journal:  Stem Cell Res Ther       Date:  2014-02-21       Impact factor: 6.832

6.  Equine mesenchymal stromal cells and embryo-derived stem cells are immune privileged in vitro.

Authors:  Yasmin Z Paterson; Nicola Rash; Elaine R Garvican; Romain Paillot; Deborah J Guest
Journal:  Stem Cell Res Ther       Date:  2014-07-30       Impact factor: 6.832

7.  Tracking of autologous adipose tissue-derived mesenchymal stromal cells with in vivo magnetic resonance imaging and histology after intralesional treatment of artificial equine tendon lesions--a pilot study.

Authors:  Florian Geburek; Kathrin Mundle; Sabine Conrad; Maren Hellige; Ulrich Walliser; Hans T M van Schie; René van Weeren; Thomas Skutella; Peter M Stadler
Journal:  Stem Cell Res Ther       Date:  2016-02-01       Impact factor: 6.832

8.  Longitudinal Cell Tracking and Simultaneous Monitoring of Tissue Regeneration after Cell Treatment of Natural Tendon Disease by Low-Field Magnetic Resonance Imaging.

Authors:  Dagmar Berner; Walter Brehm; Kerstin Gerlach; Claudia Gittel; Julia Offhaus; Felicitas Paebst; Doreen Scharner; Janina Burk
Journal:  Stem Cells Int       Date:  2016-01-10       Impact factor: 5.443

9.  The Contribution of Adipose Tissue-Derived Mesenchymal Stem Cells and Platelet-Rich Plasma to the Treatment of Chronic Equine Laminitis: A Proof of Concept.

Authors:  Mario Angelone; Virna Conti; Cristiano Biacca; Beatrice Battaglia; Laura Pecorari; Francesco Piana; Giacomo Gnudi; Fabio Leonardi; Roberto Ramoni; Giuseppina Basini; Silvia Dotti; Sabrina Renzi; Maura Ferrari; Stefano Grolli
Journal:  Int J Mol Sci       Date:  2017-10-11       Impact factor: 5.923

10.  Safety and tracking of intrathecal allogeneic mesenchymal stem cell transplantation in healthy and diseased horses.

Authors:  Danielle Jaqueta Barberini; Monica Aleman; Fabio Aristizabal; Mathieu Spriet; Kaitlin C Clark; Naomi J Walker; Larry D Galuppo; Rogério Martins Amorim; Kevin D Woolard; Dori L Borjesson
Journal:  Stem Cell Res Ther       Date:  2018-04-10       Impact factor: 6.832

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.